Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Cellectis Announces FDA Grants Orphan Drug Designation To CLLS52 (Alemtuzumab) For Lymphodepletion Regimen In UCART22, Evaluated In BALLI-01 Clinical Trial For Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Author: Benzinga Newsdesk | August 01, 2024 05:03pm

Posted In: CLLS